TECH Quote, Financials, Valuation and Earnings

Avantor, Inc. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of -43.84%. Bio-Techne Corp.'s return on equity of 3.85% beat Avantor, Inc.'s return on equity of -1.4%.

Bio-Techne Corp. has a consensus price target of $69.67, signalling upside risk potential of 17.64%. On the other hand Avantor, Inc. has an analysts' consensus of $13.32 which suggests that it could grow by 16.55%. Given that Bio-Techne Corp. has higher upside potential than Avantor, Inc., analysts believe Bio-Techne Corp. is more attractive than Avantor, Inc..

Bio-Techne Corp. has a beta of 1.464, which suggesting that the stock is 46.414% more volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.02%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.54%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Bio-Techne Corp.'s net income of $38.2M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 121.05x while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.68x versus 1.19x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of 14.91%. Bio-Techne Corp.'s return on equity of 3.85% beat Boston Scientific Corp.'s return on equity of 12.46%.

Bio-Techne Corp. has a consensus price target of $69.67, signalling upside risk potential of 17.64%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 31.02%. Given that Boston Scientific Corp. has higher upside potential than Bio-Techne Corp., analysts believe Boston Scientific Corp. is more attractive than Bio-Techne Corp..

Bio-Techne Corp. has a beta of 1.464, which suggesting that the stock is 46.414% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.54%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Bio-Techne Corp.'s net income of $38.2M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 121.05x while Boston Scientific Corp.'s PE ratio is 51.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.68x versus 7.41x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings Corp. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of -4.52%. Bio-Techne Corp.'s return on equity of 3.85% beat Envista Holdings Corp.'s return on equity of 0.5%.

Bio-Techne Corp. has a consensus price target of $69.67, signalling upside risk potential of 17.64%. On the other hand Envista Holdings Corp. has an analysts' consensus of $22.31 which suggests that it could grow by 1.45%. Given that Bio-Techne Corp. has higher upside potential than Envista Holdings Corp., analysts believe Bio-Techne Corp. is more attractive than Envista Holdings Corp..

Bio-Techne Corp. has a beta of 1.464, which suggesting that the stock is 46.414% more volatile than S&P 500. In comparison Envista Holdings Corp. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.453%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.54%. Envista Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Envista Holdings Corp. pays out -- of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than Envista Holdings Corp. quarterly revenues of $669.9M. Bio-Techne Corp.'s net income of $38.2M is higher than Envista Holdings Corp.'s net income of -$30.3M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 121.05x while Envista Holdings Corp.'s PE ratio is 263.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.68x versus 1.43x for Envista Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of 21.32%. Bio-Techne Corp.'s return on equity of 3.85% beat Pfizer Inc.'s return on equity of 10.84%.

Bio-Techne Corp. has a consensus price target of $69.67, signalling upside risk potential of 17.64%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that Bio-Techne Corp. has higher upside potential than Pfizer Inc., analysts believe Bio-Techne Corp. is more attractive than Pfizer Inc..

Bio-Techne Corp. has a beta of 1.464, which suggesting that the stock is 46.414% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.54%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Bio-Techne Corp.'s net income of $38.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 121.05x while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.68x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.